Rhumbline Advisers United Therapeutics Corp Transaction History

Rhumbline Advisers

  • $105 Billion
  • Q2 2024

A detailed history of Rhumbline Advisers transactions in United Therapeutics Corp stock. As of the latest transaction made, Rhumbline Advisers holds 130,842 shares of UTHR stock, worth $52 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
130,842
Previous 137,743 5.01%
Holding current value
$52 Million
Previous $31.6 Million 31.72%
% of portfolio
0.04%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
BUY
$228.26 - $319.04 $29.9 Million - $41.7 Million
130,842 New
130,842 $41.7 Million
Q1 2024

May 09, 2024
SELL
$210.76 - $249.51 $20,865 - $24,701
-99 Reduced 0.07%
137,743 $31.6 Million
Q4 2023

Feb 08, 2024
SELL
$214.88 - $256.94 $242,169 - $289,571
-1,127 Reduced 0.81%
137,842 $30.3 Million
Q3 2023

Nov 09, 2023
SELL
$211.82 - $248.24 $383,394 - $449,314
-1,810 Reduced 1.29%
138,969 $31.4 Million
Q2 2023

Aug 08, 2023
BUY
$205.19 - $232.99 $1.44 Million - $1.63 Million
6,997 Added 5.23%
140,779 $31.1 Million
Q1 2023

May 11, 2023
SELL
$212.99 - $276.17 $119,700 - $155,207
-562 Reduced 0.42%
133,782 $30 Million
Q4 2022

Feb 14, 2023
BUY
$205.95 - $280.43 $271,442 - $369,606
1,318 Added 0.99%
134,344 $37.4 Million
Q3 2022

Nov 10, 2022
BUY
$203.3 - $244.17 $746,517 - $896,592
3,672 Added 2.84%
133,026 $27.9 Million
Q2 2022

Aug 11, 2022
BUY
$174.81 - $241.14 $2.53 Million - $3.49 Million
14,487 Added 12.61%
129,354 $30.5 Million
Q1 2022

May 12, 2022
SELL
$166.16 - $213.96 $638,054 - $821,606
-3,840 Reduced 3.23%
114,867 $20.6 Million
Q4 2021

Feb 10, 2022
BUY
$184.32 - $216.08 $381,911 - $447,717
2,072 Added 1.78%
118,707 $25.7 Million
Q3 2021

Nov 12, 2021
SELL
$179.86 - $214.88 $842,823 - $1.01 Million
-4,686 Reduced 3.86%
116,635 $21.5 Million
Q2 2021

Aug 05, 2021
BUY
$170.47 - $211.93 $184,619 - $229,520
1,083 Added 0.9%
121,321 $21.8 Million
Q1 2021

May 06, 2021
SELL
$153.94 - $174.85 $134,235 - $152,469
-872 Reduced 0.72%
120,238 $20.1 Million
Q4 2020

Feb 10, 2021
BUY
$101.87 - $151.79 $617,943 - $920,758
6,066 Added 5.27%
121,110 $18.4 Million
Q3 2020

Nov 12, 2020
SELL
$99.9 - $121.13 $252,547 - $306,216
-2,528 Reduced 2.15%
115,044 $11.6 Million
Q2 2020

Aug 13, 2020
BUY
$92.74 - $125.82 $175,278 - $237,799
1,890 Added 1.63%
117,572 $14.2 Million
Q1 2020

May 06, 2020
BUY
$79.39 - $115.35 $765,478 - $1.11 Million
9,642 Added 9.09%
115,682 $11 Million
Q4 2019

Feb 05, 2020
BUY
$78.31 - $95.34 $61,473 - $74,841
785 Added 0.75%
106,040 $9.34 Million
Q3 2019

Oct 23, 2019
SELL
$74.85 - $85.99 $15,868 - $18,229
-212 Reduced 0.2%
105,255 $8.39 Million
Q2 2019

Aug 14, 2019
BUY
$76.06 - $120.81 $37,801 - $60,042
497 Added 0.47%
105,467 $8.23 Million
Q1 2019

May 01, 2019
SELL
$107.15 - $126.84 $443,386 - $524,863
-4,138 Reduced 3.79%
104,970 $12.3 Million
Q4 2018

Jan 31, 2019
BUY
$101.4 - $128.73 $3.03 Million - $3.85 Million
29,895 Added 37.74%
109,108 $11.9 Million
Q3 2018

Nov 07, 2018
SELL
$113.81 - $129.46 $213,507 - $242,866
-1,876 Reduced 2.31%
79,213 $10.1 Million
Q2 2018

Aug 06, 2018
SELL
$101.14 - $118.31 $141,697 - $165,752
-1,401 Reduced 1.7%
81,089 $9.18 Million
Q1 2018

May 02, 2018
SELL
$107.21 - $151.94 $428,840 - $607,760
-4,000 Reduced 4.62%
82,490 $9.27 Million
Q4 2017

Feb 09, 2018
SELL
$118.58 - $151.28 $176,565 - $225,255
-1,489 Reduced 1.69%
86,490 $12.8 Million
Q3 2017

Nov 06, 2017
BUY
$114.6 - $136.81 $10.1 Million - $12 Million
87,979
87,979 $10.3 Million

Others Institutions Holding UTHR

# of Institutions
644
Shares Held
44.9M
Call Options Held
368K
Put Options Held
410K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $18.1B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email